Trastuzumab, for example, effectively disrupts oncogenic signaling by downregulating HER2, an RTK that is commonly overexpressed in HER2-positive breast cancer, thereby promoting its internalization and degradation [229,230]. Here, ERBB2 is linked to breast carcinoma.